Opening Remarks, Call to Order and Opening of the Polls
Preliminary Procedural Remarks and Introduction
Agenda PART II
Statement Regarding the Notice of Meeting, Inspector of Elections, Presence of Quorum and Voting Procedures
Introduction of Formal Business of the Meeting:
Election of Four Class II Directors
Approval, on a Non-Binding Advisory Basis, of the Compensation of Organon's Named Executive Officers
Ratification of the Appointment of PricewaterhouseCoopers LLP as Organon's Independent Registered Public
Accounting Firm for 2023
Closing of the Polls
Announcement of Preliminary Voting Results
Adjournment of Formal Business
PART III
2022 Business Review / Chief Executive Officer Remarks
General Question and Answer Session
Conclusion of the Meeting
[Organon] Proprietary
Organon Board of Directors
DIRECTOR NOMINEE
DIRECTOR NOMINEE
DIRECTOR NOMINEE
Carrie Cox
Kevin Ali
Robert Essner
Alan Ezekowitz,
Ma. Fatima de
Helene Gayle,
Rochelle
Chairman, Organon;
Chief Executive Officer,
Former Chairman,
M.D., Ph.D.
Vera Francisco
M.D., MPH
Lazarus
Former CEO and former
Organon
President and Chief
Advisory Partner,
Chief Executive Officer,
President, Spelman
Chairman Emeritus,
Chairman of Humacyte
Executive Officer,
Third Rock Ventures, LLC
Global Baby and
College
Ogilvy & Mather
and current Chairman of
Wyeth Pharmaceuticals,
Feminine Care, Proctor &
Selecta Biosciences,
Inc.
Gamble
Inc.
DIRECTOR NOMINEE
Deborah Leone
Martha McGarry
Philip Ozuah,
Cynthia Patton
Grace Puma
Shalini Sharp
Former Partner and
Partner and Co-Head of
M.D., Ph.D.
General Counsel and
Former Executive Vice
Former Chief Financial
Chief Operating Officer,
M&A,
President and Chief
Corporate Secretary,
President, Chief
Officer, and Executive
Investment Management,
Mayer Brown LLP
Tessera Therapeutics
Operations Officer,
Vice President,
Executive Officer,
Goldman Sachs
PepsiCo
Utragenyx
Montefiore Medicine
Pharmaceutical, Inc.
[Organon] Proprietary
Executive leadership team
Kevin Ali
Chief Executive Officer
Vittorio
Nisita
Head of Global
Business Services
Aaron Falcione
Chief Human
Resources Officer
Geralyn Ritter
Head of External Affairs
& ESG
Susanne
Fiedler
Chief Commercial
Officer
Rachel Stahler
Chief Information Officer
Sandra Milligan
Head of Research &
Development
Matthew
Walsh
Chief Financial
Officer
Joseph
Morrissey
Head of Manufacturing
& Supply
Kirke Weaver
General Counsel & Corporate Secretary
ORGANON & CO.
2023 Annual Meeting of Shareholders
Tuesday, June 6, 2023
9:00 AM Eastern Daylight Time
PART I
Preliminary Procedural Remarks
Opening Remarks and Introduction of Directors and Attendees
Agenda PART II
Call to Order
Statement Regarding the Notice of Meeting, Inspector of Elections, Presence of Quorum and Voting Procedures
Opening of the Polls
Election of Four Class II Directors
Approval, on a Non-Binding Advisory Basis, of the Compensation of Organon's Named Executive Officers
Ratification of the Appointment of PricewaterhouseCoopers LLP as Organon's Independent Registered Public
Accounting Firm for 2023
Closing of the Polls
Announcement of Preliminary Voting Results
Conclusion of Formal Business
PART III
Chief Executive Officer Remarks
Question and Answer Session
Conclusion of the Meeting
2023 Organon Annual Meeting of Shareholders
June 6, 2023
Attachments
Original Link
Original Document
Permalink
Disclaimer
Organon & Co. published this content on 13 June 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 June 2023 14:30:05 UTC.
Organon & Co. is a global health care company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. The Companyâs Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, respiratory, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as health maintenance organizations, pharmacy benefit managers and other institutions. The Company operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.